Objectives: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study.
Introduction
Infection of the CNS with HIV can lead to the development of HIV-1-associated dementia, HIV-1 encephalitis or neurological disorders. Although treatment with fully active antiretrovirals (ARVs) has reduced the frequency of HIV-1 infection of the CNS, neurological disorder symptoms are still observed in HIV-1 ARV-naive and ARV-treated patients. 1 -6 It is known that HAART has an effect on HIV-1 RNA levels in CSF. 7 Due to the blood-brain barrier, ARV may not be at optimal therapeutic concentrations in the CNS compartment. Low therapeutic concentrations of the ARV could contribute to viral resistance, and consequently, lead to virological failure. 8 Such differences in ARV concentrations in several compartments could result in discordant HIV-1 RNA levels between plasma and CSF and/or ARV drug resistance mutations. 9 -12 Differences in ARV drug resistance mutations between plasma and CNS compartments have been reported as case reports or in small cohorts of patients. 9 -12 Currently, little information on the resistance patterns in the CNS is actually available in clinical practice in a large cohort of patients having a viral load (VL) .50 copies/mL in plasma and in CSF. In this study, the resistance of HIV-1 in plasma and CSF was studied and compared in a multicentre study supported by the 'Agence Nationale de Recherche sur le Sida et les Hépatites Virales' (ANRS).
Methods

Patients
We studied all CSF -plasma pairs with detectable VL (.50 copies/mL) between 2000 and 2013 in 22 centres in France and one centre in Switzerland. The indications for lumbar puncture are reserved for people affected by severe cognitive impairment without aetiological orientation. Socio-demographic and clinical data as well as treatment regimen were collected for all studied patients. Participating laboratories belong to ANRS and participate in the ANRS quality control assessment of HIV-1 drug resistance sequencing. 13 The study was approved by the scientific committee of Action Coordonnée 11-AC11 ANRS.
Genotyping resistance testing
The reverse transcriptase (RT) and protease resistance mutations were determined in each laboratory using the ANRS consensus technique (http://www.hivfrenchresistance.org), a Bayer TrueGene Kit, an Abbott ViroSeq Kit or an in-house method. In ARV-naive patients, protease and RT mutations were identified from the consensus statement of the list for genotypic surveillance of transmitted HIV-1 drug resistance. 14 In ARV-treated patients, RT and protease mutations were identified from the last International AIDS Society-USA resistance testing panel (http:// www.iasusa.org) and were interpreted with the last ANRS genotypic algorithm (version 23; http://www.hivfrenchresistance.org). According to the ANRS algorithm, the global genotypic susceptibility score (GSS) was calculated on ARV currently available (n¼18) as follows: 1 for a sensitive drug and 0 for a resistant or possible resistant drug. The GSS was also calculated according to Standford and Rega algorithms.
Statistical methods
Quantitative variables were summarized by means of median and IQR and qualitative variables by percent. Comparisons between independent groups were performed using the Kruskal -Wallis non-parametric test. The McNemar test was applied to compare the prevalence of mutations in both plasma and CSF in the same group of patients. No correction for multiple testing was made and the analysis was done with SAS (version 9.4).
Results
In total, 244 patients who experienced VL .50 copies/mL in plasma and CSF at the time of neurological disorders were HIV ARV resistance in CSF and plasma 567 JAC recruited; 89 and 155 were ARV naive and ARV treated, respectively. The main characteristics of the study population are shown in Table 1 . In the regimen of ARV-treated patients, the most frequent NRTIs prescribed were emtricitabine/lamivudine (47.5%), abacavir (25.8%) and tenofovir (25.0%), and the most frequent PIs were lopinavir (20.5%), darunavir (14.7%) and atazanavir (13.1%). Etravirine was the NNRTI most frequently prescribed (13.1%). Overall, non-B subtypes were present in 47.0% of cases with a majority of CRF02_AG (20.6%).
In ARV-naive patients, 17.9% (16/89) of patients had at least one HIV-1 resistance mutation in plasma and 17.9% (16/89) in CSF. Mutations were associated with resistance in 11.2% (10/89) and 12.4% (11/89) of patients in plasma and CSF, respectively. The concordance between CSF and plasma sequences was evidenced in 85/89 (95.5%) and 88/89 (98.9%) patients for the studied positions in RT and protease gene, respectively. The detection of mutations in CSF and not in plasma viruses was reported in 2/89 (2.2%) patients for the RT gene and in 1/89 (1.1%) patients for the protease gene ( Table 2) . Some mutations were also present in plasma and not in CSF in 2/89 (2.2%) patients for the RT gene (Table 2 ). Furthermore, 96.6% (86/89) of ARV-naive patients had viruses with a similar global GSS in the two compartments, 3.4% (3/89) with a global GSS in CSF , GSS in plasma, and none with a global GSS in CSF . GSS in plasma ( Figure 1 ).
In ARV-treated patients, the RT and protease amplification was successful for 152 and 151 cases, respectively, resulting in complete paired sequences for 148 patients. Mutations induced HIV-1 resistance at least for one drug for 111/148 (75.0%) patients and 110/148 (74.3%) in CSF and plasma, respectively. Nineteen of 152 (12.5%) patients had HIV-1 mutations only present in the CSF for the RT gene and 30/151 (19.8%) patients for the protease gene (Table 3) . Two mutations were statistically more prevalent in the CSF in comparison with the plasma for the RT gene: M41L (P ¼ 0.0455) and T215Y (P ¼ 0.0455). There was no statistically significant difference for the presence of protease gene mutations. Some patients also presented HIV-1 mutations in plasma and not in CSF: 16/152 (10.5%) and 21/151 (13.9%) for RT and protease gene, respectively ( Table 2) . One mutation for the RT gene was statistically significantly more prevalent in plasma than in CSF: T69N (P¼ 0.0455). Furthermore, 79.7% (118/148) of ARV-treated patients had viruses with a similar global GSS of current treatment in the two compartments whatever algorithm was used, 11.5% (17/148) with a global GSS in CSF , GSS in plasma and 8.8% (13/148) with a global GSS in CSF . GSS in plasma (Figure 1 ). No correlation of CNS-penetration effectiveness (CPE) score and any studied parameters was evidenced.
Discussion
In this multicentre study, the ARV resistance in 244 HIV-1 patients with neurological disorders and HIV-1 RNA load .50 copies/mL in plasma and CSF was studied in both compartments. In most cases, HIV-1 resistance was similar in plasma and CSF. However, we identified some cases where HIV-1 was more resistant in CSF than in plasma, reducing the number of future therapeutic options, in the studied population.
In ARV-naive patients, the prevalence of transmitted drug resistance was 11.2% in plasma. Similar results (9.0%) were described in the national sentinel surveillance of transmitted drug resistance in ARV-naive chronically HIV-1-infected patients in France over a decade (2001 -11) . 15 The prevalence of HIV-1 drug resistance in ARV-treated patients in this study was superior to that previously shown in 2009 in a French nationwide study (59%), possibly because the present study population was more advanced with higher VL (3.70 versus 2.57 log 10 copies/mL) and lower CD4 (230 versus 390 cells/mm 3 ). 16 Overall, a good concordance of resistance pattern was observed in CSF and plasma, but some resistance mutations can In bold, mutations appeared statistically more prevalent: in CSF, M41L (P¼0.0455) and T215Y (P¼0.0455); and in plasma, T69N (P¼0.0455).
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be detected only in CSF or in plasma. In addition, some attention should also be paid to patients with similar global GSS in both compartments, because the resistance mutation set could be different, resulting in different ARV resistance. Our results were similar to a systematic review pooling 35 reports with heterogeneous design and methods. 17 Several factors could explain the discordant presence of HIV-1 mutations and/or ARV resistance between the plasma and the CSF, such as insufficient drug exposure, 9 previous discontinuation of treatment, 18 independent replication and evolution of resistance in the CNS, 19 CNS infection leading to local immune activation 20, 21 or previous virological failure in plasma allowing archiving of ARV-resistant HIV-1 strains in the CNS compartment. 10 The CNS drug penetration appeared to be an important factor in the pathogenesis of CSF viral escape. 22 The CPE score was developed by Letendre 23 to calculate a CPE score adjusted for each regimen. In case of neurological disorders, the ART should be based not only on drug penetration but also on HIV-1 resistance in CSF. It should be mentioned that these cases of discordance between blood and CSF remain relatively uncommon. Furthermore, analysis of plasma and CNS samples also by Ultra Deep P Sequencing can provide a deeper characterization of drug resistance mutations and HIV-1 quasi-species in both compartments. This new-generation sequencing could highlight either some additional discordances or concordances with different percentages in both compartments. It is noteworthy that the two mutations statistically significantly more prevalent in CSF than in plasma were M41L and T215Y. This may be related to thymidine analogues that have a good penetration into the CNS compartment, allowing appearance of the virus mutation, probably due to drug pressure. 8 More attention has to be paid to pharmacological CNS drug penetration not only to treat neurological disorders but also to prevent ARV resistance, despite the difficulties of evaluati individual CNS drug concentration.
In conclusion, these results from a large cohort from clinical routine care evidenced discordance in HIV-1 mutations and/or resistance between the plasma and the CSF in HIV-1 patients with neurocognitive symptoms. Furthermore, in 3.4% of ARVnaive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need to perform genotypic resistance testing when VL is .50 copies/mL in CSF. GSS in CSF   9  10  11  12  14  15  16  17  18  Patients (n)  9  1  1  11  1  1  12  1  1  14  1  2  3  15  3  3  16  2  2  17  1  1 3  7  2  2  8  2  2  9  1  1  10  1 1  1  3  11  4  4  12  1  4  1  1  1  8  13  1  7  8  14  1 1  1  14  1  18  15  9  1  1  11  16  1  1  1 3 1  1  17  17  1  2  23 2  28  18  1  5  3 2 
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